Association of the Trp719Arg Polymorphism in Kinesin-Like Protein 6 With Myocardial Infarction and Coronary Heart Disease in 2 Prospective TrialsThe CARE and WOSCOPS Trials
Olga A. Iakoubova, MD, PhD*,*,
Carmen H. Tong, BS*,
Charles M. Rowland, MS*,
Todd G. Kirchgessner, PhD ,
Bradford A. Young, PhD*,
Andre R. Arellano, BS*,
Dov Shiffman, PhD*,
Marc S. Sabatine, MD, MPH ,
Hannia Campos, PhD ,
Christopher J. Packard, DSc||,
Marc A. Pfeffer, MD, PhD ,
Thomas J. White, PhD*,
Eugene Braunwald, MD, FACC ,
James Shepherd, PhD||,
James J. Devlin, PhD* and
Frank M. Sacks, MD ,
* Celera, Inc., Alameda, California
Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, New Jersey
Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts
Harvard School of Public Health, Boston, Massachusetts
|| University of Glasgow and Royal Infirmary, Glasgow, United Kingdom.

View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Adjusted Hazard Ratios for Myocardial Infarction in the CARE Study
Comparison of the KIF6 719Arg risk allele and conventional risk factors in the CARE study. Hazard ratios were adjusted for age, gender, smoking, baseline low-density lipoprotein cholesterol (LDL-C) level, baseline high-density lipoprotein cholesterol (HDL-C) level, history of diabetes, history of hypertension, and body mass index (BMI). The 719Trp homozygote was the reference group for 719Arg carriers. The 95% confidence intervals are shown.
|
|
|